Cargando…

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

BACKGROUND: Primary androgen deprivation therapy (PADT) has played an important role in the treatment of prostate cancer. We sought to identify factors of PSA progression in our series of patients with localized and locally advanced prostate cancer treated with PADT. METHODS: Six-hundred forty-nine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomioka, Atsushi, Tanaka, Nobumichi, Yoshikawa, Motokiyo, Miyake, Makito, Anai, Satoshi, Chihara, Yoshitomo, Okajima, Eijiro, Hirayama, Akihide, Hirao, Yoshihiko, Fujimoto, Kiyohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446859/ https://www.ncbi.nlm.nih.gov/pubmed/25990314 http://dx.doi.org/10.1186/s12885-015-1429-0

Ejemplares similares

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection
por: Okajima, Eijiro, et al.
Publicado: (2012)

Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid
por: Nakai, Yasushi, et al.
Publicado: (2014)

Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model
por: Inoue, Takeshi, et al.
Publicado: (2013)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer
por: Miyake, Makito, et al.
Publicado: (2014)

The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
por: Tanaka, Nobumichi, et al.
Publicado: (2015)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2017)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume
por: Hosokawa, Yukinari, et al.
Publicado: (2014)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration
por: Tanaka, Nobumichi, et al.
Publicado: (2011)

Localized prostate cancer with pelvic arteriovenous malformation treated with low‐dose‐rate brachytherapy after transcatheter embolization: Two case reports
por: Owari, Takuya, et al.
Publicado: (2019)

Overactive bladder induces transient hypertension
por: Torimoto, Kazumasa, et al.
Publicado: (2018)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Comparison of the Safety and Efficacy of Photoselective Vaporization of the Prostate (PVP) and Transurethral Enucleation with a Bipolar System (TUEB): A Single-Center Retrospective Study
por: Kiba, Keisuke, et al.
Publicado: (2020)

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method
por: Miyake, Makito, et al.
Publicado: (2021)

Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012
por: Tanaka, Nobumichi, et al.
Publicado: (2017)

Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma
por: Hori, Shunta, et al.
Publicado: (2021)

Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma
por: Shimizu, Takuto, et al.
Publicado: (2020)

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume
por: Hori, Shunta, et al.
Publicado: (2019)

Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report
por: Maesaka, Fumisato, et al.
Publicado: (2019)

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)

Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without Anesthesia
por: Nakai, Yasushi, et al.
Publicado: (2021)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Supplementary granulocyte macrophage colony‐stimulating factor to chemotherapy and programmed death‐ligand 1 blockade decreases local recurrence after surgery in bladder cancer
por: Miyake, Makito, et al.
Publicado: (2019)

Diagnostic and prognostic role of urinary collagens in primary human bladder cancer
por: Miyake, Makito, et al.
Publicado: (2017)

Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas
por: Morizawa, Yosuke, et al.
Publicado: (2016)

Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy
por: Nakai, Yasushi, et al.
Publicado: (2017)

Living‐donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome
por: Nishimura, Nobutaka, et al.
Publicado: (2020)

Rationale, design, and methods of electroencephalography-based investigation of the effects of oral desmopressin on improving slow-wave sleep time in nocturnal polyuria patients (the DISTINCT study): protocol for a single-arm, open-label, single-assignment trial
por: Torimoto, Kazumasa, et al.
Publicado: (2020)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
por: Patrikidou, Anna, et al.
Publicado: (2021)

Diagnostic markers of urothelial cancer based on DNA methylation analysis
por: Chihara, Yoshitomo, et al.
Publicado: (2013)

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study
por: Miyake, Makito, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_215d09o65t70uund54unn7qq39